Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymph node biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    303 result(s) found for: Lymph node biopsy. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-001557-46 Sponsor Protocol Number: 01 Start Date*: 2012-06-27
    Sponsor Name:Sydvestjysk Sygehus, Esbjerg [...]
    1. Sydvestjysk Sygehus, Esbjerg
    2. Odense Universitetshospital
    Full Title: Perioperativ installation of ropivacain in mastectomy – with or without axillary lymph node dissection after sentinel node diagnostics or known lymph node metastasis – A double-blind, randomized cl...
    Medical condition: Unilateral mastectomy with or without axillary lymph node dissection
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003554-23 Sponsor Protocol Number: NL68976.041.19 Start Date*: 2021-12-03
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection in early-stage ORal Cavity squamous cell carcinoma using Magnetic Resonance (MR) lymphogrAphy
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with early-stage oral cavity squamous cell carcinoma and a clinically negative neck (T1-3, N0, M0).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10004822 Biopsy of lymph node LLT
    21.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005546-42 Sponsor Protocol Number: MELISA Start Date*: 2021-06-21
    Sponsor Name:Fundacio Clinic per a la Recerca Biomedica
    Full Title: Sentinel lymph node assessment in ovarian cancer. Lymphatic mapping with two tracers and intraoperative lymphoscintigraphy.
    Medical condition: Sentinel lymph node in ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003284-21 Sponsor Protocol Number: 71151 Start Date*: 2020-01-13
    Sponsor Name:Radboudumc
    Full Title: Radio guided lymph node dissection in oligo metastatic prostate cancer patients; a feasibility study
    Medical condition: Patients diagnosed with prostate cancer upon prostate biopsy, who are suspected of having lymph node involvement based upon PSMA-PET/CT.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000333-40 Sponsor Protocol Number: 11-534 Start Date*: 2012-07-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Towards plannable breast surgery: diagnostic accuracy of microbubble enhanced Iodine-125 seed localization of the sentinel lymph node (MIB study)
    Medical condition: Patient with breast cancer with an indication for sentinel lymph node biopsy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000819-67 Sponsor Protocol Number: MTW_2020_KC01 Start Date*: 2020-07-28
    Sponsor Name:Maidstone and Tunbridge Wells NHS Trust
    Full Title: SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following t...
    Medical condition: Breast Cancer - Using SonoVue injected intradermally into the breast and contrast enhanced ultrasound to see if the cancer has spread via lymphatic channels to sentinel lymph nodes in the axilla.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-004390-28 Sponsor Protocol Number: Alexander Becherer Start Date*: 2005-03-02
    Sponsor Name:Univ.-Kl.f.Nuklearmedizin Wien
    Full Title: 11C-Acetate PET and 18F-Choline PET in Bladder Carcinoma: Prospective Validation for the Preoperative Staging
    Medical condition: Patients with bladder carcinoma who are candidates for surgery. Patients with lymph node metastases benefit from preoperative chemotherapy but in case of negative lymph nodes they undergo a toxic t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002978-13 Sponsor Protocol Number: Verde_Nano Start Date*: 2016-09-13
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Assessment of the feasibility and clinical efficacy of the ICG - 99mTc - nanocolloid for sentinel lymph node biopsy
    Medical condition: Patients with breast cancer or melanoma candidates for sentinel node biopsy surgery. The regional lymph nodes are the most common site of metastatic involvement in patients with cutaneous melanoma ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000393-20 Sponsor Protocol Number: AX-CES1.2020 Start Date*: 2020-10-23
    Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: USE OF SULFUR HEXAFLUORIDE MICROBUBBLES IN INTRAOPERATIVE SURGICAL EVALUATION OF AXILLARY LYMPH NODES IN LOCO-REGIONAL ANESTHESIA BREAST SURGERY: COMPARISON WITH THE TRADITIONAL METHODICAL. PRELIMI...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002244-25 Sponsor Protocol Number: ICG20 Start Date*: 2012-07-05
    Sponsor Name:Norfolk & Norwich University Hospital
    Full Title: Prospective feasibility study for the evaluation of indocyanine green and near-infrared imaging in sentinel lymph node biopsy for cutaneous melanoma patients: The "RED-GREEN-BLUE" melanoma study.
    Medical condition: Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025655 Malignant melanoma of skin LLT
    20.0 100000004865 10068478 Sentinel lymphadenectomy LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003825-56 Sponsor Protocol Number: SENTINELSEEK-HC Start Date*: 2020-02-28
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: An exploratory prospective, open-label, unicentric study with cross-over design, comparing Lymphoseek® vs. albumin nanocolloid for Image-Guided Sentinel Lymph Node Mapping in Head and Neck, Melanom...
    Medical condition: The hypothesis is that 99mTc-tilmanocept (Lymphoseek®) can be used safely and will be comparable to nanocolloidal human serum nanocolloidal albumin in Head and Neck, Melanoma and Breast Cancer sent...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000549-21 Sponsor Protocol Number: MAGSTAR Start Date*: 2015-03-16
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St. Thomas' NHS Foundation Trust
    Full Title: MAGnetic versus STAndard technique for sentinel node biopsy in breast cancer compared in a Randomised controlled trial
    Medical condition: Many women with breast cancer undergo sentinel lymph node biopsy in order to identify if the breast cancer has spread (metastasis) to the lymph nodes. This study is aimed at evaluating a new magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004045-33 Sponsor Protocol Number: NL70759.100.19 Start Date*: 2020-09-07
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer
    Medical condition: Prostate cancer (PCa) is the most common malignancy amongst men in Western countries. In order to select the most suitable treatment for patients diagnosed with PCa, it is important to stage accu...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003068-28 Sponsor Protocol Number: 77946 Start Date*: 2021-09-29
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection of cervical occult lymph node metastases in patients with parotid gland carcinoma by means of sentinel node biopsy using 68-galium-tilmanocept PET-CT.
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with parotid gland carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026329 Malignant neoplasm of parotid gland LLT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002470-42 Sponsor Protocol Number: 72010 Start Date*: 2021-11-29
    Sponsor Name:Univeristy Medical Center Utrecht
    Full Title: Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: A proof of concept study
    Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with thyroid carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005788-28 Sponsor Protocol Number: ICG1 Start Date*: 2014-01-24
    Sponsor Name:Landeskrankenhaus Fedkirch
    Full Title: Influence of Body Mass Index on the identification rate of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Medical condition: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003133-18 Sponsor Protocol Number: NL.58570.091.16 Start Date*: 2017-01-19
    Sponsor Name:radboudumc
    Full Title: Preoperative staging by combidex MRI in patients with resectable esophageal carcinoma, a feasibility study
    Medical condition: Detection of locoregional lymph node metastases in patients with resectable esophageal carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005219-98 Sponsor Protocol Number: PH3-01 Start Date*: 2012-10-08
    Sponsor Name:Galena Biopharma, Inc
    Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)
    Medical condition: Operable early-stage, node-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10071113 Node-positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001474-25 Sponsor Protocol Number: SVM9122 Start Date*: 2012-01-02
    Sponsor Name:Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin
    Full Title: A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node disse...
    Medical condition: The trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003152-37 Sponsor Protocol Number: MK3475-A18/ENGOT-cx11/GOG-3047 Start Date*: 2020-05-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
    Medical condition: High-risk locally advanced cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 22:32:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA